title: Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.
abstract: Rheumatoid arthritis (RA) is one of the most common and most debilitating joint diseases, producing high personal, social, and economic costs.(1,2) Patients with RA suffer pain and functional losses, often followed by disability and premature death. Although the etiology of RA is unknown, substantial efforts have been directed toward studying the transition of the joint from normal to diseased. The maintenance of normal joint architecture and function requires equilibrium between the synthesis and degradation of the specialized extracellular matrices that make up bone, cartilage, and tendons. In RA, the balance of tissue remodeling is disturbed,(3) and excessive proteolytic degradation of the joint matrices leads to joint destruction.(4,5) The early phase of RA is characterized by the infiltration of immune and inflammatory cells into the synovium and by hyperplasia of the fibroblasts in the synovial lining. This leads to pannus formation, cartilage breakdown, and eventual bone destruction.(1,2) Through the use of an experimental mouse model of RA, Li and colleagues(6) have implicated plasmin as an essential component of the early phase of RA, as reported in this issue of The American Journal of Pathology.
authors.affiliation: Sidney Kimmel Cancer Center, San Diego, California, USA.
authors.forename: Martin O
authors.initials: MO
authors.lastname: Judex
authors.forename: Barbara M
authors.initials: BM
authors.lastname: Mueller
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000378:metabolism*; D005341:Fibrinolysin / Q000378:metabolism*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D051379:Mice; D010958:Plasminogen / Q000378:metabolism*; D010960:Plasminogen Activators / Q000378:metabolism*; D013927:Thrombosis
chemical_list: D010958:Plasminogen; D010960:Plasminogen Activators; D005341:Fibrinolysin
references.citation: Nat Cell Biol. 2001 Mar;3(3):267-75
references.pmid: 11231576
references.citation: Endocrinology. 1999 Nov;140(11):5030-5
references.pmid: 10537128
references.citation: Ann N Y Acad Sci. 2001;936:226-36
references.pmid: 11460480
references.citation: Am J Pathol. 2002 Mar;160(3):917-26
references.pmid: 11891190
references.citation: J Immunol. 2002 Apr 1;168(7):3577-85
references.pmid: 11907122
references.citation: Thromb Haemost. 2002 Mar;87(3):493-501
references.pmid: 11916082
references.citation: Arthritis Rheum. 2002 Apr;46(4):934-45
references.pmid: 11953970
references.citation: Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14
references.pmid: 11994741
references.citation: Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1421-6
references.pmid: 12231560
references.citation: Front Biosci. 2003 Jan 1;8:d1-8
references.pmid: 12456318
references.citation: J Exp Med. 2002 Dec 2;196(11):1461-71
references.pmid: 12461081
references.citation: J Clin Invest. 2003 Jan;111(1):35-41
references.pmid: 12511586
references.citation: Curr Pharm Des. 2004;10(1):39-49
references.pmid: 14754404
references.citation: Cancer Metastasis Rev. 1992 Nov;11(3-4):291-311
references.pmid: 1423820
references.citation: Physiol Rev. 1993 Jan;73(1):161-95
references.pmid: 8419965
references.citation: J Biol Chem. 1994 Feb 11;269(6):4360-6
references.pmid: 7905877
references.citation: Eur J Immunol. 2004 Apr;34(4):1208-16
references.pmid: 15048732
references.citation: J Clin Invest. 2004 Jun;113(11):1596-606
references.pmid: 15173886
references.citation: J Rheumatol. 2004 Jul;31(7):1229-37
references.pmid: 15229936
references.citation: J Biol Chem. 2004 Sep 3;279(36):37528-34
references.pmid: 15247268
references.citation: Lab Invest. 1982 Mar;46(3):321-43
references.pmid: 7062727
references.citation: Clin Physiol Biochem. 1983;1(2-5):225-84
references.pmid: 6241121
references.citation: Blood. 2001 Jun 15;97(12):3941-50
references.pmid: 11389038
references.citation: Thromb Haemost. 1999 Aug;82(2):742-7
references.pmid: 10605777
references.citation: Trends Pharmacol Sci. 2000 Mar;21(3):103-8
references.pmid: 10689364
references.citation: Thromb Haemost. 1999 Sep;82 Suppl 1:4-7
references.pmid: 10695477
references.citation: J Immunol. 2000 Apr 15;164(8):4340-7
references.pmid: 10754334
references.citation: Arthritis Rheum. 2000 Aug;43(8):1710-8
references.pmid: 10943860
references.citation: Cell Mol Life Sci. 2000 Jan 20;57(1):25-40
references.pmid: 10949579
references.citation: N Engl J Med. 2001 Mar 22;344(12):907-16
references.pmid: 11259725
references.citation: Genes Dev. 1995 Apr 1;9(7):794-807
references.pmid: 7705657
references.citation: Nat Med. 1996 Mar;2(3):287-92
references.pmid: 8612226
references.citation: Ann Rheum Dis. 1996 Dec;55(12):888-94
references.pmid: 9014582
references.citation: Coron Artery Dis. 1997 Jan;8(1):9-18
references.pmid: 9101117
references.citation: Am J Physiol. 1997 Nov;273(5 Pt 1):E996-1004
references.pmid: 9374687
references.citation: Ann Rheum Dis. 1997 Dec;56(12):705-6
references.pmid: 9496148
references.citation: APMIS. 1999 Jan;107(1):80-5
references.pmid: 10190283
references.citation: Clin Exp Rheumatol. 1999 Jul-Aug;17(4):485-98
references.pmid: 10464565
references.citation: Am J Pathol. 2005 Mar;166(3):783-92
references.pmid: 15743790